Ken Fisher's NBIX Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 112,242 shares of Neurocrine Biosciences, Inc. (NBIX) worth $15.92 M, representing 0.01% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2019, adding 47,257 shares. Largest reduction occurred in Q2 2025, reducing 7,717 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +17,447 | Add 18.40% | 112,242 | $141.83 |
| Q3 2025 | +7,255 | Add 8.29% | 94,795 | $140.38 |
| Q2 2025 | -7,717 | Reduce 8.10% | 87,540 | $125.69 |
| Q1 2025 | +3,153 | Add 3.42% | 95,257 | $110.60 |
| Q4 2024 | +23,834 | Add 34.91% | 92,104 | $136.50 |
| Q3 2024 | +4,930 | Add 7.78% | 68,270 | $115.22 |
| Q2 2024 | -1,826 | Reduce 2.80% | 63,340 | $137.67 |
| Q1 2024 | +4,939 | Add 8.20% | 65,166 | $137.92 |
| Q4 2023 | -1,600 | Reduce 2.59% | 60,227 | $131.76 |
| Q3 2023 | -179 | Reduce 0.29% | 61,827 | $112.50 |
| Q2 2023 | -2,136 | Reduce 3.33% | 62,006 | $94.30 |
| Q1 2023 | -126 | Reduce 0.20% | 64,142 | $101.22 |
| Q4 2022 | -848 | Reduce 1.30% | 64,268 | $119.44 |
| Q3 2022 | -5,362 | Reduce 7.61% | 65,116 | $106.21 |
| Q2 2022 | -4,178 | Reduce 5.60% | 70,478 | $97.48 |
| Q1 2022 | +9 | Add 0.01% | 74,656 | $93.75 |
| Q4 2021 | +5,453 | Add 7.88% | 74,647 | $85.17 |
| Q3 2021 | +7,545 | Add 12.24% | 69,194 | $95.90 |
| Q2 2021 | +3,473 | Add 5.97% | 61,649 | $97.33 |
| Q1 2021 | +746 | Add 1.30% | 58,176 | $97.26 |
| Q4 2020 | -1,791 | Reduce 3.02% | 57,430 | $95.86 |
| Q3 2020 | -4,006 | Reduce 6.34% | 59,221 | $96.17 |
| Q2 2020 | -1,340 | Reduce 2.08% | 63,227 | $122.00 |
| Q1 2020 | -2,208 | Reduce 3.31% | 64,567 | $86.55 |
| Q4 2019 | -6,252 | Reduce 8.56% | 66,775 | $107.50 |
| Q3 2019 | -1,393 | Reduce 1.87% | 73,027 | $90.10 |
| Q2 2019 | +47,257 | Add 173.98% | 74,420 | $84.43 |
| Q1 2019 | -477 | Reduce 1.73% | 27,163 | $88.10 |
| Q4 2018 | -507 | Reduce 1.80% | 27,640 | $71.42 |
| Q3 2018 | -3,195 | Reduce 10.19% | 28,147 | $122.96 |
| Q2 2018 | +31,342 | New Buy | 31,342 | $98.24 |
| Q1 2018 | -5,025 | Sold Out | 0 | $0.00 |
| Q4 2017 | -28 | Reduce 0.55% | 5,025 | $77.61 |
| Q3 2017 | +5,053 | New Buy | 5,053 | $61.35 |
Ken Fisher's Neurocrine Biosciences Investment FAQs
Ken Fisher first purchased Neurocrine Biosciences, Inc. (NBIX) in Q3 2017, acquiring 5,053 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Neurocrine Biosciences, Inc. (NBIX) for 34 quarters since Q3 2017.
Ken Fisher's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q2 2019, adding 74,420 shares worth $6.28 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 112,242 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $15.92 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 112,242 shares, as reported at the end of Q4 2025.